Mr. Eric So reports

HELUS PHARMA APPOINTS MICHAEL COLA AS CHIEF EXECUTIVE OFFICER TO LEAD NEXT PHASE OF SCALE AND EXECUTION

Cybin Inc., doing business as Helus Pharma, has appointed Michael Cola as chief executive officer, effective immediately.

Mr. Cola's appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of phase 2 data for HLP004 this quarter and phase 3 top line data for HLP003 in the fourth quarter of 2026. In parallel, Helus continues to build a broad and defensible intellectual property estate spanning its multiasset pipeline, with more than 350 patent applications filed globally and over 100 patents granted. The company is advancing differentiated programs designed to address serious mental health disorders. With the transition from early clinical development to later-stage execution under way, the company is increasingly focused on global regulatory engagement and long-term commercial planning. This evolution underscores the importance of experienced leadership across drug development, capital formation and global scale-up.

"Michael brings a rare combination of deep neuroscience expertise, global commercialization experience and proven capital markets leadership," said co-founder and executive chairman Eric So. "As Helus advances its differentiated mental health pipeline, his track record of building first-in-class CNS franchises and scaling global organizations makes him uniquely suited to lead Helus as we work to translate our science into meaningful therapies for patients and long-term value for shareholders."

With more than 30 years of experience across neuroscience, rare disease and specialty pharmaceuticals, Mr. Cola brings deep expertise in guiding innovative CNS assets through development and into global markets, building high-performance organizations and creating long-term shareholder value. His career spans senior leadership roles across research and development, commercialization, corporate strategy and capital formation, positioning him to lead Helus through its next phase of growth.

"I am honoured to join Helus at this pivotal and energizing moment," said Mr. Cola. "With highly differentiated HLP003 clinical data already in hand and a robust pipeline of novel compounds in development, Helus is uniquely positioned to advance a new paradigm in the treatment of serious mental health disorders. I'm excited to work alongside the board and the Helus team to build on this foundation and translate scientific progress into lasting patient and shareholder impact."

Mr. Cola holds a bachelor's degree in biology from Ursinus College, a master of science in biomedical science and engineering from Drexel University and studied bioengineering at the University of Pennsylvania, where he also worked as a biomedical engineer at its affiliated hospital.

About Helus Pharma

Helus Pharma, the commercial operating name of Cybin, founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs -- novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.